SK Biopharmaceuticals Co Ltd
KRX:326030
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
75 700
125 900
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
SK Biopharmaceuticals Co Ltd
Operating Margin
SK Biopharmaceuticals Co Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | KR |
| Market Cap | 8.2T KRW |
| Operating Margin |
13%
|
| Country | JP |
| Market Cap | 776 550.9T JPY |
| Operating Margin |
-83%
|
| Country | US |
| Market Cap | 749.1B USD |
| Operating Margin |
35%
|
| Country | UK |
| Market Cap | 440.4B GBP |
| Operating Margin |
3%
|
| Country | DK |
| Market Cap | 2.7T DKK |
| Operating Margin |
44%
|
| Country | US |
| Market Cap | 348B USD |
| Operating Margin |
28%
|
| Country | US |
| Market Cap | 251.1B USD |
| Operating Margin |
34%
|
| Country | CH |
| Market Cap | 200.1B CHF |
| Operating Margin |
32%
|
| Country | UK |
| Market Cap | 161.8B GBP |
| Operating Margin |
21%
|
| Country | CH |
| Market Cap | 171.5B CHF |
| Operating Margin |
31%
|
| Country | US |
| Market Cap | 150.1B USD |
| Operating Margin |
22%
|
SK Biopharmaceuticals Co Ltd
Glance View
SK Biopharmaceuticals Co., Ltd., a prominent player in the global biopharmaceutical industry, emerged as a distinctive entity out of one of South Korea's largest conglomerates, the SK Group. This pharmaceutical jewel draws its strength from innovation in the neurology and oncology sectors, fields brimming with both challenge and opportunity. At its core, SK Biopharmaceuticals is dedicated to the research, development, and commercialization of novel medications, with a significant focus on disorders impacting the central nervous system. Their pipeline and commercial activities revolve around cutting-edge therapies, such as the epilepsy drug Cenobamate, which has gained a foothold in both the U.S. and European markets. This drug, marketed under different names like Xcopri in the U.S., is a testament to the company's ability to leverage robust R&D capabilities into profitable products. Revenue generation for SK Biopharmaceuticals is predominantly driven by the sales of their innovative therapeutic solutions, as well as strategic collaborations with a network of global partners. They engage in a lifecycle approach where they not only develop and launch their own drugs but also license out their intellectual property, enhancing revenue streams through royalties and milestone payments. This hybrid model of sales and strategic partnerships showcases a deft mix of scientific prowess and commercial acumen, key to sustaining and propelling growth in a competitive market. Additionally, they continuously invest in research and alliances, aiming to expand their portfolio beyond existing successes, while targeting unmet medical needs that mirror their core strengths. This balanced approach positions SK Biopharmaceuticals not just as a standalone drugmaker, but as a dynamic player in shaping future therapies in their chosen niches.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on SK Biopharmaceuticals Co Ltd's most recent financial statements, the company has Operating Margin of 13.2%.
You don't have any saved screeners yet
